Archives of Dermatology · 1994 · 98 citations · 22 references
MedicineImmunologyOncologyCancer ImmunologyHematologic OncologyMonoclonal AntibodiesCutaneous LymphomaCytotoxic T Lymphocyte ResponsesHelper T Cell SubsetsLymphoid TissueT Cell BiologyTumor-infiltrating LymphocytesCell Surface ProteinsCutaneous T-cell Lymphoma ImmunopathologyLymphocyte SubtypesMonoclonal Antibodies In CancerPeripheral Blood Lymphocyte AnalysisT Cell ImmunologyT-cell BiomarkersTumor Burden Measurement
BACKGROUND AND DESIGN: To accurately assess tumor burden in cutaneous T-cell lymphoma as well as to determine the number of residual normal circulating T cells, it is necessary to accurately distinguish malignant cells. Because cutaneous T-cell lymphoma cells regularly display many normal phenotypic markers of T cells (CD2+, CD3+, CD4+) these surface proteins have been of limited value. We have used a set of monoclonal antibodies with specificity for those T-cell receptor proteins containing variable regions on the beta chain to distinguish normal from malignant T cells in patients with cutaneous T-cell lymphoma. RESULTS: The results revealed an unanticipated and profound expansion of the malignant cell populations (59% to 87% of blood T cells) in six patients with total T-cell counts in the normal or near normal range. By subtracting the percentages of malignant T cells, identified in this manner, from the total T-cell counts, we found that the residual normal T-cell compartments were small (0 to 0.155 x 10(9)/L) in four of the six patients. Sézary cell counts by peripheral blood smear analysis by routine light microscopy underestimated the number of malignant T cells. Markedly elevated CD4/CD8 ratios (10 to 90) occurred in all cases, reflecting expansion of the CD4+ malignant population and parallel reduction of the normal residual CD8+ subset. CONCLUSIONS: Patients with erythrodermic cutaneous T-cell lymphoma often have markedly depressed levels of normal blood T cells, to the range seen in advanced acquired immunodeficiency syndrome, and absolute numbers of malignant cells substantially exceed those recognized with less sensitive techniques.
22
Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings.
Ervin H. Epstein, David L. Levin, Joseph D. Croft et al. · PubMed · 1972 · 400 citations
Mycosis Fungoides in the United States
Martin A. Weinstock · JAMA · 1988 · 286 citations
Cutaneous T cell lymphoma: characterization by monoclonal antibodies
PC Kung, Berger Cl, G Goldstein et al. · Blood · 1981 · 240 citations · Full text
Medicine, Dermatology, Oncology +13